# US 5,585,262 A · Process for the production of a viable cell culture infected by a multiple sclerosis-associated virus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,585,262 A
- Document ID: US5585262A
- Status: Granted
- Kind: A
- Application number: 08/157,060
- Filed: 1994-02-02
- Granted: 1996-12-17
- Earliest claimed: 1992-04-03
- Assignees: Bio Merieux; Universite Joseph Fourier
- Inventors: Herve Perron; Jean-Marie Seigneurin
- Web page: https://patentgrep.com/patent/US5585262A

## CPC

- G01N 33/56983: {Viruses}
- C07K 14/005: from viruses
- C07K 16/10: RNA viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/85: for animal cells
- C12N 2710/16622: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/10021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2740/10022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2740/10051: Methods of production or purification of viral material
- G01N 2469/20: Detection of antibodies in sample from host which are directed against antigens from microorganisms
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention relates to a process for in vitro culture of cells infected by a virus associated with multiple sclerosis and to the infected cell lines thus produced. The process is the cultivation of human cells infected by a viral strain to obtain at least one culture of primary cells infected by the said viral strain, along with the cultivation of non-infected human cells permissive to the viral strain to obtain at least one permissive culture, followed by cocultivation of at least one sample of a culture of infected primary cells and one sample of the permissive culture to obtain a first infected derived culture, then cultivating in series of the first infected derived culture. The invention is used in particular in the pharmaceutical diagnostics industry sector. In the preferred process, the infected cells are leptomeningeal cells and the permissive cells are leptomeningeal cells or plexuschoroideus cells.

## Claims

### Claim 1

A process for producing a viable cell culture infected by at least one human viral strain associated with multiple sclerosis, said process comprising:
(a) cultivating infected leptomeningeal cells to establish a primary culture of cells infected with said viral strain,
(b) cultivating non-infected leptomeningeal cells or plexus choroideus cells to establish a permissive, non-infected culture,
(c) cocultivating said infected cells from the primary culture with cells from the permissive culture to obtain a first derived culture of infected leptomeningeal cells or infected plexus choroideus cells; and
(d) cocultivating cells from the derived culture with cells from the permissive culture to obtain a subculture of viable infected cells.